Contineum Therapeutics Inc CTNM

$9.86 +0.08 (0.82%)

Valuation

Market cap
367,933,000
Revenue TTM
$0
Net income TTM
$-59,980,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
265,800
Avg volume
895,702
Day's range
$9.36 – $10.15
Shares out
37,621,000
Stochastic %K
55%
Beta
1.07
Analysts
Moderate Buy
Price target
$21.17

Price

Company profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain...

Show more

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 333 5280
Website
https://www.contineum-tx.com
Address
3565 General Atomics Court, Suite 200, San Diego, United States

Latest news

Stocktwits

Merlintrader Nov 10, 7:30 PM
$CTNM Contineum (CTNM): $244.5M cash, runway through mid-2029 Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
GTA_Terminal Nov 9, 12:49 PM
Unusual options activity in $CTNM. Both sides are getting paid for here. Somebody expects a move, they just don't agree which way. Read the full article for the full details: https://globaltradersacademy.com/articles/contineum-ctnm-technical-levels-options-flow-mixed-between-8-67-and-11-54?utm_source=stocktwits&utm_medium=social
0 replies
d_risk Nov 5, 3:02 AM
$CTNM - Contineum Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +261.9% above peer average (42,975 vs 11,874 across 655 peers). Contineum says it depends heavily on PIPE-791, its lead candidate in early clinical development. It warns that setbacks in development, approval or commercialization of PIPE-791 or its other candidates would materially harm the business. #Biotechnology #ClinicalTrials #RegulatoryRisk #PharmaceuticalR&D #InvestorRisk 🟢 Added 🟠 Removed https://d-risk.ai/CTNM/10-Q/2026-11-03
0 replies
Merlintrader Nov 4, 3:35 PM
$CTNM — Contineum Q3: net loss $18.7M ($0.49/share); cash and securities $244.5M. R&D $16.0M, up 45% y/y, as PIPE-791 work continues. CTNM Stock Hub: Contineum Therapeutics News, PIPE-791 and PROPEL-IPF https://www.merlintrader.com/contineum-therapeutics-ctnm-stock-hub/
0 replies
focafoca99 Nov 3, 9:16 PM
$CTNM released its third-quarter 2026 financial results in a press release.
0 replies
Merlintrader Oct 31, 9:49 PM
$CTNM closed the week at $9.39 (+13.0% w/w, +0.6% Friday), below the 50-day SMA ($12.70) and below the 200-day ($13.55). RSI14 43.0. Support $6.72, resistance $13.86 (20-day range, middle). New hub updated: https://www.merlintrader.com/contineum-therapeutics-ctnm-stock-hub/
0 replies
BX_MoneyMakr Oct 29, 1:57 PM
$CTNM 🚀
0 replies
XQuise Oct 28, 4:08 PM
$CTNM 🐌👈🏻👈🏻📉📈⏳
0 replies